# Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

> **NCT02731742** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- Neoplasms, Advanced

## Interventions

- **BIOLOGICAL:** MK-1966
- **DRUG:** SD-101

## Key facts

- **NCT ID:** NCT02731742
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-22
- **Primary completion:** 2018-01-08
- **Final completion:** 2018-01-08
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The study was terminated early due to business reasons.
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02731742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02731742, "Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02731742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*